Scinai Immunotherapeutics Ltd.
SCNI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.01 | 0.01 | -0.00 |
| FCF Yield | -234.96% | -431.03% | -145.17% | -31.38% |
| EV / EBITDA | -0.40 | -1.96 | -1.24 | -3.46 |
| Quality | ||||
| ROIC | -71.59% | -58.88% | -44.05% | -35.99% |
| Gross Margin | -88.15% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | -1.32 | 1.44 | 1.25 | 0.90 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 36.65% | -23.68% | -7.09% | 69.09% |
| Safety | ||||
| Net Debt / EBITDA | -0.02 | -1.71 | -0.71 | -1.14 |
| Interest Coverage | -6.00 | -1,216.44 | -2.19 | -3.23 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 9.52 | -380.89 | -466.84 | -487.71 |